Jump to content
RemedySpot.com

XMRV Global Action -Christmas Gift

Rate this topic


Recommended Posts

Posted

http://on.fb.me/fGbfBN

XMRV GLOBAL ACTION

XMRV Global Action's

Transcription of Sam

Shad's interview with

Annette Whittemore

and Dr Mikovits on

Retro-contamination

papers

By XMRV Global Action

Thursday, 23 december 2010

Ready for some good news?

Here is our early Christmas gift from XMRV Global

Action.

Renewed HOPE from Nevada Newsmakers and the

WPI.

Below is our " Close " transcription of the Nevada

NewsMakers TV interview with Sam Shad, Annette

Whittemore and Dr Judy Mikovits, December 22,

2010.

Discussion topics:

The Retrovirology Contamination papers;

medical politics; " All Systems still at Go "

@ the WPI & their collaborators; and *patients,

don't panic - this continues to be a time of great

(science-based) hope!*.

NB: If you're pressed for time, jump to the end of

this post for the key, optimistic messages from

Sam, Annette, and Judy, bolded and in quotes.

````

Link:

http://www.nevadanewsmakers.com/video/nnmstreamb.asp?showID=1192

Several options for downloading/viewing here:

http://www.nevadanewsmakers.com/default.asp

Interview starts around 3:00 minutes.

Sam: Annette, can we just start out with a brief

simple explanation of what neuro-immune diseases

are, including ME and CFS?

Annette: They are systemic diseases that impact

the nervous system and immune system. ME/CFS is

a very, very complex disease and we believe that it

is infectious, that there are very many organisms

involved, and that it will require a comprehensive set

of treatments to bring about (clinical) change.

Sam: The retrovirus XMRV that has showed up in

research was found to be in a majority of folks not

only suffering with ME/CFS but also prostate cancer.

What has been the result in terms of the worldwide

reaction to this?

Judy: We have had a very exciting year, interactions

with Norway, Spain, Belgium. Different groups

throughout the US, in the US in the SE and NE. Many

groups are into the research, excited about the

research, and actually detecting XMRV in their

patient populations.

Sam: 4 papers were published this week in the

journal Retrovirology and according to the WSJ it

demonstrated according to the authors how easy it

could be for mouse contamination to skew results on

XMRV. Thoughts on Retrovirology papers?

Judy: We've shown in the paper that we published

last year, and in a confirmation study by Harvey Alter

and Dr Lo at the FDA that it's necessary to do

multiple different kinds of tests, and one single test

(PCR) won't give you clear detection of XMRV. And

because XMRV is so closely related to some mouse

viruses, it's very important not to do work in mouse

lab, and to actually isolate the virus and show an

immune response to the virus. We were well aware

that it is possible to potentially skew results (with

contamination). And hence multiple tests required.

Sam: Were you surprised at the response to these

papers?

Annette: I was. I thought it was a well concerted

effort by this group to make sure that everyone knew

about it prior to our being able to have a response.

We weren't notified about it and given the

opportunity to respond. … We want to thank you for

this opportunity to respond and pretty much calm

everyone down. It really doesn't change the findings

(of XMRV in ME/CFS). It doesn't change the work

that we've done whatsoever. And that we're moving

forward in very positive way.

Sam: What do u think the motivation was, that they

didn't contact you, as you were the prime research

centre?

Judy: It's difficult to comment on the motivation of

others. It is an attempt to make certain that the

patients maybe aren't served, and that XMRV is not

important. I think there is great fear about the

public health risk of this virus in this disease and

cancers.

Sam: Would you explain that more deeply.

Judy: If our results and the confirmatory results

hold true, as many as 20 million Americans could be

infected with a new human retrovirus of uncertain

pathogenic potential. That means you don't have to

get sick, but you might. And that's 20 M Americans,

and that's 20x the amt of HIV that was in this

country in the height of the HIV epidemic in 1995.

So there is great concern about public health. And

that's why everything that gets published about

XMRV gets great attention each time.

Sam: One of the easiest ways to understand this

retrovirus is AIDS, correct?

Annette: That's a good example, and the other one

is HTLV1 – certainly looking at those viruses we can

learn something, and we can learn how they

integrate and so forth. . But this (XMRV/MRV's) is a

brand new family (of human retroviruses). But

there's a lot to be learned, and before we make any

clear statements we want to do the good hard

research. I am very proud of our group, and the fact

that they didn't take their first results and simply go

with those, but looked long and hard at this, and

used 4 methods to be absolutely sure they knew

what they found.

Sam: Whenever there's a discovery like this, and

this is a huge discovery, there will always be a huge

fight in the medical community when you have these

kinds of changes.

Judy: Absolutely. It is a huge discovery. And as I

said, of potential public health high significance. So

it will always be a level of understanding – we have

to learn how to detect the virus. There is a lot to be

learned. There will always be a lot of push-back.

The best science generates more questions than

answers, and that's certainly what's happened here.

Continued at 11:08

Sam: Your research is published in the past year

that the reasons that other scientists have trouble

recreating the results is that they are not doing the

research in the same way. Why? That just seems to

be illogical. Why are they not doing the research in

the same way?

Judy: Scientists usually do things that they do well,

and the advances that we've had in the past decade,

that is in molecular testing, high throughput, with an

instrument to measure is it (the virus) there or not,

have really replaced the old fashioned way of

culturing. It's very difficult to culture virus, do

antibody testing which we've done, and it takes a lot

of time and significant resources. It's the hope and

perhaps bias of other researchers that since we can

detect HIV with these nucleic acid testing (fast

throughput), we should be able to do so with XMRV.

But it's too early in the discovery process for XMRV.

So we have to do the very labor intensive isolation of

the virus from patients and it's very difficult.

Annette: I wanted to make another comment and I

think it got glossed over in these last

(contamination) papers. But really what you're

talking about is researchers at the NIH that have

done this work, the Cleveland Clinic, the U of Utah,

Cornell University, (the FDA), and WPI. So there are

others that are very successful at this and are

moving their research forward as well. So we're lucky

to have those significant groups of researchers

working on this.

Sam: What's the role of politics in all of this

Annette: Laughs… there is certainly a lot of politics

in medicine. I think whenever there's money,

prestige, power, change, there's going to be a lot of

interest. Certainly in this case, there is a lot of

money involved. Pharma, disability companies,

insurance companies, government run health care

systems. And they all have a stake in this. It's

going to create a massive change in the way things

are done and the way these people are treated. And

it's going to cost. So the pushcback right now can be

related to political issues.

Sam: Blood supply around the world. People are

giving blood, and they are not being tested for this

(XMRV/MRV's).

Judy: Blood donors are not being tested because we

have not been able to develop the high throughput

tests yet. We've been working with NHLBI and

various Blood Working group that was set up the day

our paper was published last year, and we had a very

successful meeting (BP Advisory Council) last week,

and it was voted on last week that there was enough

concern and enough data to suggest that CFS

patients NOT give blood.

So until we can learn more, a question is asked, and

if you have ever had CFS, you are not permitted to

give blood. So in light of new discoveries we are

erring on the side of caution and working very hard

to develop those (high throughput) tests.

Sam: People CAN get tested now for XMRV?

Annette: Yes. The clinical lab is called VIPDx.

Ours is a research lab at WPI, but the clinical WPI

lab is getting ready to open but we're not yet set

up. But VIPDx is the current lab, and if a physician

requests that test (for XMRV), they will get that

test. Can go to VIPDx website to learn more.

Judy: And we culture virus, and determine if the

patient has an antibody to the virus, and that is the

Gold Standard assay. Culture test can take 45 days,

but we're not in a hurry. The key is to get the

answer right.

Sam: How is the new institute?

Annette: Very excited. We're up and running.

We've been working closely with physician this past

week to set up medical practice. Meanwhile getting

instrumentation up and running in research lab has

taken some time. All going smoothly now. We're

very excited. Anyone that wants to come by can

come by and see what's happening there. We're very

very proud of it. We're very excited to have all of

the pieces in one home.

Sam:

I guess bottom line from this entire discussion

today is for people not to panic. Things are still

moving forward. Nothing has changed – it's just

that there are simply different opinions.

Annette:

Absolutely.

Judy:

As one would expect (that there would be

different opinions). And this is really a great time

of HOPE. Because we've also determined in our

research this year - and that will be coming out

published very soon - we're understanding WHY

the (XMRV) virus hurts the immune system.

We're understanding what's going wrong to make

you sick, and that's another step to making people

well. So it's a great time of excitement and

research around the world. We expect

treatments next year (2011).

Sam:

2011. Can't wait!

Join the conversation

You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.

Guest
Reply to this topic...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

Loading...
×
×
  • Create New...